Table 6.
Comparison of the diagnostic utility of single CA15-3 and CEA assays and combinations of these markers in the diagnosis of metastatic BC (MBC)
| Biomarker | SN [%] | SP [%] | AUC | References |
|---|---|---|---|---|
| (MBC vs. BC without mestastases) | Wang et al. (2017) | |||
| CEA | 56.7 | 92.0 | 0.806 | |
| CA15-3 | 44.5 | 84.5 | 0.743 | |
| CEA+CA 15–3 | 68.9 | 88.0 | 0.817 | |
| CEA+TPS | 78.7 | 82.0 | 0.863 | |
| CA15-3+CA125 | 52.4 | 91.5 | 0.708 | |
| (Patients with distant metastasis) | Zhang et al. (2021d) | |||
| CEA | 57.1 | 87.4 | 0.755 | |
| CA15-3 | 59.2 | 94.1 | 0.821 | |
| CEA+CA15-3 | 81.6 | 83.8 | 0.855 | |
| CEA+CA 15–3+TPS | 83.7 | 79.4 | 0.866 | |
| TPS+CA15-3+CEA+CA125 | 85.7 | 78.2 | 0.846 | |
| (patients with occult metastasis in three years) | ||||
| CEA | 39.7 | 94.8 | 0.725 | |
| CA15-3 | 47.9 | 94.0 | 0.744 | |
| CEA+CA15-3 | 60.3 | 83.9 | 0.764 | |
| CA 15–3+TPS | 57.5 | 91.0 | 0.799 | |
| CEA+CA 15–3+TAP | 57.5 | 91.0 | 0.799 | |
| CA 15–3+CA 125+TAP | 57.5 | 91.0 | 0.799 | |
| TPS+CA15-3+CEA+CA125 | 57.5 | 91.0 | 0.799 | |
TPS, tissue polypeptide specific antigen